ezetimibe has been researched along with naloxone in 6 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | ezetimibe (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Galetin, A; Gill, KL; Houston, JB | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, H; Chen, S; Hotz, K; La Placa, DB; Nguyen, N; Peterkin, V; Stevens, JC; Tukey, RH; Yang, YS | 1 |
2 review(s) available for ezetimibe and naloxone
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for ezetimibe and naloxone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Topics: Adult; Aged; Female; Glucuronides; Glucuronosyltransferase; Humans; In Vitro Techniques; Intestinal Mucosa; Intestines; Kidney; Liver; Male; Metabolic Clearance Rate; Microsomes; Middle Aged; Organ Specificity; Pharmaceutical Preparations; Predictive Value of Tests; Protein Binding; Serum Albumin, Bovine; Substrate Specificity; Young Adult | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation.
Topics: Alleles; Animals; Anticholesteremic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Azetidines; Biocatalysis; Camptothecin; Dimethyl Sulfoxide; Enzyme Induction; Ezetimibe; Gene Expression; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Kinetics; Liver; Male; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Naloxone; Pharmaceutical Preparations; Phenobarbital; UDP-Glucuronosyltransferase 1A9 | 2010 |